Weight Loss Drugs Market Analysis 2026

An investigation into the exorbitant costs of Novo Nordisk's diabetes and weight-loss medications Ozempic and Wegovy in the US has been opened by the US Senate. The head of the Health, Education, Labour and Pensions (HELP) Committee, Sen. Bernie Sanders of Vermont, acknowledged the work of Novo Nordisk's scientists in creating these medications, but cautioned that millions of people who cannot afford them would not benefit from them. Sanders also emphasised the predicament that American insurance and the government are in as a result of the exorbitant prices of these potentially life-saving medications. He also questioned Lars Fruergaard Jørgensen, CEO of Novo Nordisk, on how the price is set and how much is spent on R&D. Novo Nordisk said that it spent $5 billion on research and development in 2023 and will spend more than $6 billion this year to increase manufacturing for GLP-1s, but it declined to reveal production expenses. The business underlined the significance of medicine accessibility as well as the intricacies of the healthcare sector.

Updates on the Food and Drug Administration's drug shortage database indicate that Eli Lilly's weight loss drug Zepbound and diabetes drug Mounjaro would be in limited availability into the second quarter of this year due to rising demand. There is a shortage of all Zepbound and Mounjaro dosages, with the exception of the 2.5-milligram ones. Incretin medicines, which are injectable medications, have become increasingly popular as a means of assisting patients in losing substantial weight over time. In an effort to boost output, Eli Lilly and Novo Nordisk, its competitor, are investing in manufacturing and supply capacity, which should lead to a gradual increase in production through 2024 and beyond. By the end of 2023, the company will have doubled its capacity for producing incretin medications, and it anticipates producing at least 1.5 times as many sellable doses as it did in the second half of 2023.

A nine-month investigation into the connection between diabetes, weight-loss medications like Novo Nordisk's Wegovy, and suicidal thoughts has come to an end by the European Union drug authority. The Pharmacovigilance Risk Assessment Committee, which keeps an eye on the adverse effects of medications, has not discovered any proof that these medications cause suicidal thoughts. Following the revelation of the EMA's results, Novo Nordisk's shares, a Danish drugmaker, increased by almost 2%. The review focused on medications containing either semaglutide or liraglutide, both GLP-1 targeting chemicals. It started in July when Iceland's health authorities noted three incidents of patients considering suicide or self-harm after using Novo's pharmaceuticals. After analysing data from a sizable US study, the EMA concluded that there was no correlation between semaglutide use and suicide ideation. The findings of an additional EMA investigation likewise refuted the idea that GLP-1 medications increase a person's risk of suicidal thoughts or behaviours. Moreover, a preliminary evaluation conducted in January by the U.S. Food and Drug Administration revealed no connection between GP-1 medications and suicidal ideation or behaviour. Since July of last year, the Medicines and Healthcare Products Regulatory Agency in Britain has been investigating a potential connection between GLP-1 medicines and suicidal or self-harming ideas. Dr. Alison Cave, the chief safety officer of the organisation, stated that the review is still ongoing and that she will "communicate any further advice to patients and healthcare professionals as appropriate." GLP-1 receptor agonists were first created to help diabetic people manage their blood sugar levels. They also slow down digestion and lessen appetite.